GSK India announced Q4 and FY26 results with 10% PAT growth to ₹1012 crore and 290 bps EBITDA margin expansion to 34%.
The Board recommended a final dividend of ₹57 per equity share for the year ended 31st March 2026.
Supply chain disruptions constrained topline growth, prompting enhanced resilience measures and contingency planning.
Oncology portfolio showed strong growth with Jemperli's new approval and market authorization received for Blenrep.